The dynamic and reversible acetylation of proteins, catalysed by histone acetyltransferases (HATs) and histone deacetylases (HDACs), is a major epigenetic regulatory mechanism of gene transcription 1 and is associated with multiple diseases. Histone deacetylase inhibitors are currently approved to treat certain cancers, but progress on the development of drug-like histone actyltransferase inhibitors has lagged behind 2 . The histone acetyltransferase paralogues p300 and CREB-binding protein (CBP) are key transcriptional co-activators that are essential for a multitude of cellular processes, and have also been implicated in human pathological conditions (including cancer 3 ). Current inhibitors of the p300 and CBP histone acetyltransferase domains, including natural products 4 , bi-substrate analogues 5 and the widely used small molecule C646 6,7 , lack potency or selectivity. Here, we describe A-485, a potent, selective and drug-like catalytic inhibitor of p300 and CBP. We present a high resolution (1.95 Å) co-crystal structure of a small molecule bound to the catalytic active site of p300 and demonstrate that A-485 competes with acetyl coenzyme A (acetyl-CoA). A-485 selectively inhibited proliferation in lineage-specific tumour types, including several haematological malignancies and androgen receptor-positive prostate cancer. A-485 inhibited the androgen receptor transcriptional program in both androgen-sensitive and castration-resistant prostate cancer and inhibited tumour growth in a castration-resistant xenograft model. These results demonstrate the feasibility of using small molecule inhibitors to selectively target the catalytic activity of histone acetyltransferases, which may provide effective treatments for transcriptional activator-driven malignancies and diseases.
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To identify novel small molecule inhibitors of p300, we conducted a virtual ligand screen based on compound docking to the binding pocket of the bi-substrate analogue Lys-CoA, in a proposed open conformation (Supplementary Table 1 ). Approximately 800,000 compounds were screened in silico and around 1,300 commercially available compounds were tested in a direct radioactive p300/CBP HAT assay. This led to two confirmed hits, a hydantoin (Fig. 1a, 1 ) and a conjugated thiazolidinedione (Fig. 1a, 2 ), which were similar to the previously described hits Rtt109 8 and C375
6
, respectively. Our optimization of the hydantoin focused on improving enzymatic and cellular activity, generating the amine-substituted indane spirooxazolidinedione, compound R (Fig. 1a, 3 ). Converting compound R to a urea improved its microsomal stability, and by deactivating potential sites of metabolism using fluorine substitution, we discovered A-485 (Fig. 1a, 4) as well as the inactive analogue A-486 (Fig. 1a, 5) . A-485 was at least 1,000-fold more potent than previously described p300 cell-permeable tool compounds; these included C646 6 (Supplementary Table 2 ), which was inactive at concentrations of up to 10 μ M under our assay conditions.
To further characterize the ability of A-485 to inhibit p300 HAT activity, we used a time-resolved fluorescence resonance energy transfer (TR-FRET) assay that measures the acetylation of a biotinylated histone H4 peptide. A-485 inhibited the activity of the p300-BHC (bromodomain HAT-C/H3) domain, with a half maximal inhibitory concentration (IC 50 ) of 9.8 nM; it also inhibited CBP-BHC (IC 50 = 2.6 nM) (Fig. 1b, c) , and similar results were observed in the absence of ethylenediaminetetraacetic acid (EDTA; Extended Data Fig. 1a ). By contrast, the inactive analogue A-486 was approximately 1,000-fold less potent towards both p300 (IC 50 > 10,000 nM) and CBP (IC 50 = 9,032 nM) than A-485. Surface plasmon resonance experiments indicated that A-485 bound to p300 HAT with a K d of 15 ± 1 nM (s.d.) and displayed a slow off-rate (k off = 1.3 ± 0.01 × 10 −3 s −1
, t 1/2 = 531 ± 4.5 s (s.d.) (Fig. 1d ), whereas A-486 bound to p300 HAT roughly 1,000-fold more weakly (K d = 20,000 ± 1,000 nM (s.d.) and displayed a very fast off-rate (k off > 0.3 s −1 ) (Fig. 1e) . To provide additional evidence that A-485 binds to p300-BHC, we used a thermal shift assay that determined that both Lys-CoA and A-485 increased the thermostability of p300-BHC by 5.8 °C (Extended Data Fig. 1b) . A-485 was assayed against other HAT family members and did not inhibit the activity of p300/CBP-associated factor (PCAF), HAT1, MYST3, MYST4, TIP60 or GCN5L2 at 10 μ M (Supplementary Table 3 ); it was selective over bromo-and extraterminal bromodomain proteins (Supplementary Table 4 ) and more than 150 non-epigenetic targets (Supplementary Tables 5-7 ). The compound displayed substantial (greater than 90%) binding to dopamine and serotonin transporters at 10 μ M, along with modest inhibition of Polo-like kinase 3 (IC 50 = 2.7 μ M). As A-485 does not achieve significant brain exposure (Supplementary Table 13) , it is unlikely to modulate these transporters in vivo.
To definitively establish the binding mode of A-485 and to delineate its specific interactions with p300, we determined the X-ray crystal structure of the fully active human p300 HAT domain: amino acids 1,287-1,666 (with auto-inhibitory internal loop deletion of amino acids 1,523-1,554), plus K1637R and M1652G mutations (Δ p300 HAT), in complex with A-485, at 1.95 Å resolution (data collection shown in Extended Data Fig. 2 ). Comparison with structures of the inactive Δ p300 HAT Y1467F mutant in complex with acetyl-CoA 9 (Extended Data Fig. 1c ) or Δp300 HAT in complex with Lys-CoA 10 ( Fig. 2a ) confirms that the A-485 binding site overlaps with that for acetylCoA, but not the peptide substrate binding site. Additionally, two molecules of Δ p300 HAT are oriented in such a way that the Lys-1558 of one molecule inserts into the lysine substrate tunnel of a symmetry-related molecule (Extended Data Fig. 3 ), highlighting the inherent accessibility of the inhibitor-bound p300 peptide site for lysine presented in the KXXK sequence motif 10, 11 . The methyl-urea of A-485 is inserted through the L1 loop, where it makes two equivalent hydrogen bonds to the backbone carbonyl of Gln-1455 (Fig. 2b) . Two other notable hydrogen bonds are made between the 4′ carbonyl of the oxazolidinedione and Ser-1400, and between the amide carbonyl and a coordinated water molecule. The majority of the remaining molecular interactions are hydrophobic; these include the fluorophenyl ring, which sits in a hydrophobic pocket that expands by means of a shift in helix 3 to accommodate its size (Fig. 2c) . Consistent with its lack of activity, the urea moiety of A-486 would be expected to clash with Gln-1455 and Lys-1456 on the side of the L1 loop.
Since substantial sequence divergence between HATs has been reported previously 12 , we used our determination of the p300 HAT domain structure to gain insight into the selectivity of A-485 (when compared with other HATs) for p300/CBP; this specificity is likely to stem primarily from the L1 loop, which is absent in other HATs (Extended Data Fig. 4a ). Superpositioning the HAT domains of a wide range of HAT family members (hPCAF, hMYST3, hHAT1, hTIP60 and hGCN5) over that of A-485 reveals that each would be predicted to clash with A-485, rendering it improbable that the other HATs would be capable of making the necessary structural accommodations to provide potent binding. For example, the indane ring of A-485 would interfere with the alpha backbone of the motif A helix of PCAF (Extended Data  Fig. 4b ). These structural superpositions are consistent with the HAT inhibitor specificity that we observe for A-485 (Supplementary Table 3 ). The activity assay IC 50 for inhibition increased linearly with increasing concentrations of acetyl-CoA (Fig. 2d) , confirming competitive inhibition with acetyl-CoA. Using a peptide substrate binding assay (AlphaLISA), we demonstrated that unlabelled peptide competed with binding whereas A-485 did not, confirming that the latter is not competitive with the peptide substrate (Extended Data Fig. 4c ). Together, these results indicate that A-485 is a catalytic inhibitor of p300/CBP that competes with acetyl-CoA.
Previous genetic studies have indicated that p300/CBP preferentially acetylates histone H3K18/K27, but not H3K9 13 . In a high content microscopy-based assay 14 (Fig. 3a) , a three-hour treatment of prostate adenocarcinoma PC-3 cells with A-485 resulted in a dose-dependent decrease in H3K27Ac, with a half maximal effective concentration (EC 50 ) of 73 nM; the same was not true for H3K9Ac (EC 50 > 10,000 nM). Under the same conditions, A-486 was inactive (Fig. 3a) , and only modest inhibition was observed upon treatment with C646 (Extended Data Fig. 5a ). For all treatments with A-485, inhibition of H3K18Ac was similar to that of H3K27Ac (Supplementary Table 8) , and inhibition of both p300/CBP acetylation sites was sustained after 24 hours, in multiple cell lines. To broadly assess the cellular selectivity of A-485, we evaluated an array of H3 and H4 epigenetic marks 14 . We confirmed that A-485 inhibited only H3K27Ac and H3K18Ac, and that A-486 was inactive, indicating that A-485 was selective for p300/CBP over other HATs and histone methyltransferases in cells (Fig. 3b and Extended Data Fig. 5b) . Similar results were observed using western letter reSeArCH Fig. 5c ). In addition to histone substrates, we further confirmed by mass spectrometry analysis that A-485 caused a marked decrease in multiple acetylation sites found within the p300/ CBP activation loop (Supplementary Table 9) 11 . Inhibition of acetylation of the p300/CBP amino acid residues K1499Ac and K1535Ac was further confirmed by site-specific antibodies via western blotting (Extended Data Fig. 5d ). Treatment with A-485 did not alter p300 or CBP protein levels (Extended Data Fig. 5e ).
Since p300 and CBP are involved in the development and progression of multiple human malignancies [15] [16] [17] , we evaluated the ability of A-485 to inhibit proliferation across 124 cancer cell lines encompassing diverse lineages. (Fig. 3c, Supplementary Table 10 ). The broadest sensitivity was observed in haematological tumours, where A-485 exhibited potent activity in most multiple myeloma cell lines, and in a subset of acute myeloid leukaemia lines and non-Hodgkin's lymphoma lines. By contrast, multiple solid tumour lines including melanoma, small cell lung cancer and triple-negative breast cancer were substantially less sensitive to A-485. Notably, we observed that A-485 was a potent inhibitor of proliferation in androgen receptor-positive (AR + ), but not androgen receptor-negative (AR − ), prostate cancer cell lines 18 (Extended Data Fig. 5f ). To validate these results, we knocked down p300/CBP using short interfering RNA (siRNA) and confirmed that the growth of AR + LnCaP-FGC cells was inhibited; we also confirmed the inhibition of H3K18Ac and H3K27Ac, but not H3K9Ac (Extended Data Fig. 6 ). Despite the differences in proliferation sensitivity, A-485 induced a comparable decrease in H3K27Ac in all five prostate cancer cell lines. These results indicate that A-485 selectively inhibits haematological and prostate cancer cell proliferation, and that inhibition of p300/CBP-mediated global histone acetylation does not necessarily translate to an anti-proliferative phenotype.
As p300 is a key co-activator of AR activity 17, 19 and is upregulated during prostate cancer progression 16, 20 , we evaluated whether A-485 modulated AR transcriptional activity. Treatment of the androgendependent LnCaP-FGC cell line with A-485 attenuated dihydrotestosterone (DHT) stimulated prostate-specific antigen (PSA) expression more potently than did similar treatment with the AR antagonist enzalutamide (Fig. 4a) ; A-486 was inactive. This inhibition by A-485 was observed at both early (7 h) and late (24 h) time points after the treatment, suggesting that AR transcriptional activity was inhibited directly. Additional AR-dependent genes, TMPRSS2 and SLC45A3, were also inhibited by A-485 (Extended Data Fig. 7a ), and A-485 further inhibited ARs beyond the basal activity observed upon androgen deprivation (Extended Data Fig. 7b ). Similar results were observed in VCaP cells, another androgen-dependent prostate adenocarcinoma cell line (Extended Data Fig. 7c, d ). These gene expression changes resulted in dose-dependent reductions in protein levels; A-485 inhibited the induction of PSA upon DHT stimulation and further reduced basal PSA expression upon androgen depletion (Extended Data Fig. 7e ).
As A-485 does not act as an AR antagonist (Extended Data Fig. 8a ), we evaluated the effects of A-485 on H3K27Ac deposition and AR occupancy at the PSA enhancer using chromatin immunoprecipitation (ChIP). DHT stimulation of LnCaP-FGC cells for six hours induced an increase in H3K27Ac deposition (Fig. 4b ) and AR binding (Fig. 4c) at the androgen response element of the PSA enhancer. Treatment with A-485 and enzalutamide both reduced H3K27Ac deposition (Fig. 4b) , but only enzalutamide decreased AR occupancy (Fig. 4c) , suggesting that p300/CBP is important for AR trans-activation but not AR complex formation. Given that p300 regulates AR activity downstream of ligand binding, 22Rv1 cells that are AR dependent but proliferate in the absence of androgens, and which express AR splice variants, should still respond to p300/CBP inhibition. Indeed, A-485 inhibited proliferation in the absence of androgens, and decreased the expression of PSA, at early (7 h) and late (24 h) time points, whereas A-486 and enzalutamide were inactive (Extended Data Fig. 8b, c) .
To evaluate AR-dependent global transcription changes, we performed gene expression profiling (Fig. 4d) . In LnCaP-FGC cells, the analysis of 217 genes that were modulated by DHT indicated that, after six hours, A-485 had antagonized the expression of the upregulated genes in a pattern almost identical to that produced by enzalutamide. However, in contrast to enzalutamide, A-485 did not reverse the expression of a subset of genes that were repressed by DHT treatment, establishing that p300 acts as an AR co-activator. A-485 also induced downregulation of 40% of these DHT-responsive genes in androgen-depleted 22Rv1 cells (Fig. 4d) , and (as with the LnCaP-FGC cells) did not modulate the DHT-repressed genes. By contrast, enzalutamide was inactive in these cells (Fig. 4d) . We also assessed the global changes of gene expression upon A-485 treatment at this early (6 h) time point, when the regulation of gene expression was likely to be direct. At both low and high concentrations, A-485 predominantly conferred gene downregulation, providing further evidence that p300/CBP primarily acts to regulate gene expression positively (Supplementary Table 11 ). We performed Ingenuity upstream regulator analysis, which indicated that both enzalutamide and A-485 inhibited hormone signalling pathways as expected in LnCaP-FGC cells, but that only A-485 induced robust inhibition in multiple other signalling pathways and transcriptional regulators including MYC (Extended Data Fig. 9 ). Indeed, A-485 robustly decreased MYC expression, whereas enzalutamide had no effect (Fig. 4e, Extended Data Fig. 10a ). MYC is strongly correlated with prostate cancer progression
21
, is an important p300 target in CBPdeficient cancers 22 and is a key oncogenic transcription factor that is regulated by superenhancer regions containing p300/CBP (identified by high densities of H3K27Ac
23
).
Since A-485 treatment inhibited the proliferation and AR-dependent transcription of castration-resistant prostate cancer cells, and displayed a promising pharmacokinetic profile (Supplementary Table 12) , we evaluated whether A-485 could inhibit tumour growth in vivo using an AR-positive, patient-derived castration-resistant prostate cancer model (the LuCaP-77 CR xenograft model). After tumours were established in SCID male mice, twice daily intraperitoneal injections of A-485 induced 54% tumour growth inhibition after 21 days of dosing (P < 0.005 as compared to vehicle control, Fig. 4f ). In addition, in tumour-bearing animals, dosing with A-485 for seven days induced a decrease in the mRNA levels of MYC and the AR-dependent gene SLC45A3 at three hours post-dosing, and (for MYC) a decrease in the protein level (Extended Data Fig. 10b, c) , indicating that A-485 inhibited p300-mediated transcriptional activity in vivo. However, at 16 hours post-dosing on the seventh day, A-485 drug levels in the plasma and tumour decreased as compared to 3 hours (Extended Data  Fig. 10d ). Concomitant with this decrease, expression of SLC45A3 and MYC rebounded to pre-treatment levels, indicating that A-485 did not inhibit these markers at Ctrough levels under the twice-daily dosing regimen employed. A-485 induced a moderate 9% body weight loss, and the animals recovered rapidly upon completion of the A-485 dosing regimen (Extended Data Fig. 10e) . In summary, we have overcome the long-standing challenge of develop ing a drug-like HAT inhibitor by identifying a first-in-class highly potent, selective, cell and in vivo active p300/CBP catalytic inhibitor, A-485. A similar approach can also be applied more broadly to develop inhibitors of other HATs. Our results underscore the value of therapeutically targeting the HAT activity of p300/CBP, and represent a major advance on the road towards evaluating the clinical utility of HAT inhibitors for multiple human diseases.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Fig. 1 Peptide binding was assessed using an AlphaLISA-based peptide substrate binding assay as described in the Supplementary Information. All data were normalized to the p300-BHC-biotin peptide complex signal, set at 100%. All measurements are the result of n = 29 technical replicates over n = 2 independent experiments. Error bars represent s.d. of the technical replicates. Source data for c is provided. A representative western blot of n = 2 independent biological replicates is shown. d, 22Rv1 cells were treated with 0.3 μ M or 3 μ M A-485, or DMSO as a control (marked as C), for one hour and processed for western blotting as described in the Supplementary Information. e, Cells were treated with 3 μ M A-485 (marked as A), or DMSO as a control (marked as C), for 24 hours and processed for western blotting as described in the Supplementary Information. f, A-485 exhibits similar inhibition of H3K27Ac in AR + and AR − prostate cancer cells (experiment performed as in Fig. 3a) but is selectively anti-proliferative in AR + cells (data from Fig. 3c are shown) . For c-e gel source data, see Supplementary Fig. 1. letter reSeArCH For animal studies, a one sided t-test was used to determine the number of animals needed to obtain 80% power at alpha = 0.05. For this, if there is 48% tumor reduction compared to that of vehicle group measured at the same time, n=8 animals per group will give 80% power.
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Data exclusions
Describe any data exclusions. No data were excluded from the analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
For Figure 4a , one attempt at replication failed as the experiment did not pass quality control and was discarded. All other attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice were randomized into treatment groups using Studylog software (Studylog Systems, Inc., South San Francisco, CA) based on tumor volume.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Partial blinding for animal studies was used. A different technician formulated and dosed compounds while the main investigator randomized and measured tumor volumes during the study.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.) A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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Software Policy information about availability of computer code 7. Software
Describe the software used to analyze the data in this study.
Commercial software was used to analyzed all data in this study as described in each section of the on-line methods. These include Microsoft Excel, Prism GraphPad 5, Biacore T200 Evaluation software, Bio-Rad CFX 3.1 Manager, Rosetta Resolver, Ingenuity Pathway Analysis, and MaxQuant.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Compounds disclosed can be made available by Abbvie upon request.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
All antibodies used in this study are described in Supplementary Table 14 of this study. Antibody validation was performed as described in reference 14 of the study.
Eukaryotic cell lines
a. State the source of each eukaryotic cell line used. The source of all eukaryotic cells in this study are described in Supplementary  Table 10 of the study.
b. Describe the method of cell line authentication used. Cell lines were authenticated using GenePrint 10 STR Authentication Kit (Promega, Madison, WI) and results of authentication are provided in Supplementary Table  10 of the study.
c. Report whether the cell lines were tested for mycoplasma contamination.
Cell lines were tested for mycoplasma using MycoAlert Detection Kit (Lonza, Walkersville, MD) and all lines tested negative.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
For animal studies, 16 week old male C.B.-17 SCID mice were used.
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Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study did not involve human research participants.
